



13 October 2022

ASX ANNOUNCEMENT

ImpediMed Quarterly Results and Investor Conference Call Notification

ImpediMed Limited (ASX:IPD) advises it will release its Appendix 4C Cash Flow Statement and Quarterly Results for the period ending 30 September 2022, on Wednesday 19th October 2022.

Investors are invited to join a live webinar and Q&A hosted by Interim CEO & Board Member Mr David W. Anderson at 4.30 pm (AEDT) on Wednesday 19th October 2022.

To pre-register, please follow this link:

<https://s1.c-conf.com/diamondpass/10026062-ghxqwp.html>

Registered participants will receive a calendar notification with dial in details and a PIN for fast-track access to the call.

Approved for release by Interim CEO & Board Member Mr David W. Anderson.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.